NVS
Price
$97.46
Change
-$1.64 (-1.65%)
Updated
Dec 18, 04:25 PM (EDT)
44 days until earnings call
NVSEF
Price
$97.43
Change
-$1.34 (-1.36%)
Updated
Dec 16 closing price
Ad is loading...

NVS vs NVSEF

Header iconNVS vs NVSEF Comparison
Open Charts NVS vs NVSEFBanner chart's image
Novartis AG
Price$97.46
Change-$1.64 (-1.65%)
Volume$1.28K
CapitalizationN/A
Novartis AG
Price$97.43
Change-$1.34 (-1.36%)
Volume$955
CapitalizationN/A
NVS vs NVSEF Comparison Chart
Loading...
NVS
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
NVSEF
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
NVS vs. NVSEF commentary
Dec 19, 2024

To understand the difference between Novartis AG - ADR (NVS) vs. Novartis AG - Ordinary Shares (Registered) (NVSEF) it is enough to know the definitions of ADR

ADR - American depositary receipt (ADR) is a certificate issued by a U.S. depositary bank representing a specified number of shares (often 1 share) of a foreign company's stock. ADRs are denominated in U.S. dollars and trade on U.S. stock markets and OTC depending on the ADRs classification.

COMPARISON
Comparison
Dec 19, 2024
Stock price -- (NVS: $99.10 vs. NVSEF: $97.43)
Brand notoriety: NVS and NVSEF are both not notable
Both companies represent the Pharmaceuticals: Major industry
Current volume relative to the 65-day Moving Average: NVS: 116% vs. NVSEF: 1%
Market capitalization -- NVS: $197.93B vs. NVSEF: $216.52B
NVS [@Pharmaceuticals: Major] is valued at $197.93B. NVSEF’s [@Pharmaceuticals: Major] market capitalization is $216.52B. The market cap for tickers in the [@Pharmaceuticals: Major] industry ranges from $739.66B to $0. The average market capitalization across the [@Pharmaceuticals: Major] industry is $86.34B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

NVS’s FA Score shows that 3 FA rating(s) are green whileNVSEF’s FA Score has 2 green FA rating(s).

  • NVS’s FA Score: 3 green, 2 red.
  • NVSEF’s FA Score: 2 green, 3 red.
According to our system of comparison, NVS is a better buy in the long-term than NVSEF.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

NVS’s TA Score shows that 4 TA indicator(s) are bullish while NVSEF’s TA Score has 4 bullish TA indicator(s).

  • NVS’s TA Score: 4 bullish, 4 bearish.
  • NVSEF’s TA Score: 4 bullish, 3 bearish.
According to our system of comparison, both NVS and NVSEF are a good buy in the short-term.

Price Growth

NVS (@Pharmaceuticals: Major) experienced а -1.03% price change this week, while NVSEF (@Pharmaceuticals: Major) price change was -1.33% for the same time period.

The average weekly price growth across all stocks in the @Pharmaceuticals: Major industry was -2.43%. For the same industry, the average monthly price growth was -3.05%, and the average quarterly price growth was -1.91%.

Reported Earning Dates

NVS is expected to report earnings on Jan 31, 2025.

Industries' Descriptions

@Pharmaceuticals: Major (-2.43% weekly)

The Major Pharmaceuticals industry includes companies that are involved in various processes of creating drugs to treat/prevent diseases. These companies engage in research, testing and manufacturing, as well as the distribution of pharmaceuticals into markets. Johnson & Johnson, Merck & Co., Inc., Pfizer Inc. and Novartis are among the largest companies in this category.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
NVSEF($217B) has a higher market cap than NVS($198B). NVSEF has higher P/E ratio than NVS: NVSEF (29.50) vs NVS (23.38). NVS YTD gains are higher at: 1.898 vs. NVSEF (-2.566). NVS (18.3B) and NVSEF (17.8B) have comparable annual earnings (EBITDA) . NVS has more cash in the bank: 14B vs. NVSEF (11.2B). NVS has less debt than NVSEF: NVS (26.3B) vs NVSEF (28.3B). NVSEF has higher revenues than NVS: NVSEF (53.1B) vs NVS (46.7B).
NVSNVSEFNVS / NVSEF
Capitalization198B217B91%
EBITDA18.3B17.8B103%
Gain YTD1.898-2.566-74%
P/E Ratio23.3829.5079%
Revenue46.7B53.1B88%
Total Cash14B11.2B125%
Total Debt26.3B28.3B93%
FUNDAMENTALS RATINGS
NVS vs NVSEF: Fundamental Ratings
NVS
NVSEF
OUTLOOK RATING
1..100
5699
VALUATION
overvalued / fair valued / undervalued
1..100
13
Undervalued
12
Undervalued
PROFIT vs RISK RATING
1..100
2559
SMR RATING
1..100
2222
PRICE GROWTH RATING
1..100
6274
P/E GROWTH RATING
1..100
9087
SEASONALITY SCORE
1..100
5050

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

NVSEF's Valuation (12) in the null industry is in the same range as NVS (13) in the Pharmaceuticals Major industry. This means that NVSEF’s stock grew similarly to NVS’s over the last 12 months.

NVS's Profit vs Risk Rating (25) in the Pharmaceuticals Major industry is somewhat better than the same rating for NVSEF (59) in the null industry. This means that NVS’s stock grew somewhat faster than NVSEF’s over the last 12 months.

NVS's SMR Rating (22) in the Pharmaceuticals Major industry is in the same range as NVSEF (22) in the null industry. This means that NVS’s stock grew similarly to NVSEF’s over the last 12 months.

NVS's Price Growth Rating (62) in the Pharmaceuticals Major industry is in the same range as NVSEF (74) in the null industry. This means that NVS’s stock grew similarly to NVSEF’s over the last 12 months.

NVSEF's P/E Growth Rating (87) in the null industry is in the same range as NVS (90) in the Pharmaceuticals Major industry. This means that NVSEF’s stock grew similarly to NVS’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
NVSNVSEF
RSI
ODDS (%)
Bullish Trend 2 days ago
70%
Bullish Trend 2 days ago
71%
Stochastic
ODDS (%)
Bullish Trend 2 days ago
50%
Bullish Trend 2 days ago
46%
Momentum
ODDS (%)
Bearish Trend 2 days ago
44%
Bearish Trend 2 days ago
55%
MACD
ODDS (%)
Bearish Trend 2 days ago
45%
Bearish Trend 2 days ago
46%
TrendWeek
ODDS (%)
Bearish Trend 2 days ago
44%
Bearish Trend 2 days ago
49%
TrendMonth
ODDS (%)
Bearish Trend 2 days ago
39%
Bearish Trend 2 days ago
45%
Advances
ODDS (%)
Bullish Trend 20 days ago
46%
Bullish Trend 22 days ago
43%
Declines
ODDS (%)
Bearish Trend 3 days ago
45%
N/A
BollingerBands
ODDS (%)
Bullish Trend 2 days ago
60%
Bullish Trend 2 days ago
63%
Aroon
ODDS (%)
Bearish Trend 2 days ago
29%
Bearish Trend 2 days ago
45%
View a ticker or compare two or three
Ad is loading...
NVS
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
NVSEF
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
ETFs / NAMEPrice $Chg $Chg %
SJNK25.48-0.03
-0.12%
SPDR® Blmbg ST HY Bd ETF
BAUG44.23-0.07
-0.16%
Innovator U.S. Equity Buffer ETF Aug
MGOV19.99-0.04
-0.20%
First Trust Intermediate Gvt Opps ETF
HIYS25.72-0.06
-0.21%
Invesco High Yield Select ETF
EQAL49.82-0.46
-0.91%
Invesco Russell 1000 Equal Weight ETF

NVS and

Correlation & Price change

A.I.dvisor indicates that over the last year, NVS has been loosely correlated with AZN. These tickers have moved in lockstep 49% of the time. This A.I.-generated data suggests there is some statistical probability that if NVS jumps, then AZN could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To NVS
1D Price
Change %
NVS100%
+1.36%
AZN - NVS
49%
Loosely correlated
+1.43%
SNY - NVS
40%
Loosely correlated
+6.65%
GSK - NVS
39%
Loosely correlated
+1.94%
RHHBY - NVS
37%
Loosely correlated
+0.84%
JNJ - NVS
35%
Loosely correlated
+1.78%
More

NVSEF and

Correlation & Price change

A.I.dvisor tells us that NVSEF and SNYNF have been poorly correlated (+27% of the time) for the last year. This A.I.-generated data suggests there is low statistical probability that NVSEF and SNYNF's prices will move in lockstep.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To NVSEF
1D Price
Change %
NVSEF100%
N/A
SNYNF - NVSEF
27%
Poorly correlated
+7.45%
SNY - NVSEF
21%
Poorly correlated
+6.65%
NVS - NVSEF
20%
Poorly correlated
+1.36%
KYKOF - NVSEF
7%
Poorly correlated
N/A
GIKLY - NVSEF
6%
Poorly correlated
+2.19%
More